| Phase 4 |
| NCT06282874 |
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases |
Carcinoma, Non-Small-Cell Lung |
Active, Not Recruiting |
| Phase 3 |
| NCT06858410 |
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK… |
Neoadjuvant Non-Small Cell Lung Cancer |
Not Yet Recruiting |
| NCT04841811 |
MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+… |
Lung Cancer |
Active, Not Recruiting |
| Phase 2 |
| NCT05536505 |
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC |
MRD |
Recruiting |
| NCT06092086 |
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC |
ALK Positive Non-small Cell Lung Cancer |
Recruiting |
| NCT07120698 |
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) |
NSCLC (Non-small Cell Lung Cancer) |
Recruiting |
| NCT07198841 |
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C… |
Lung Cancer (Non-Small Cell) |
Recruiting |
| NCT07375316 |
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan… |
Non Small Cell Lung Cancer |
Recruiting |
| NCT05163249 |
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC |
Carcinoma, Non-Small-Cell Lung |
Active, Not Recruiting |
| NCT07134413 |
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC |
NSCLC |
Not Yet Recruiting |
| NCT07416058 |
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50%… |
Lung Adenocarcinoma |
Not Yet Recruiting |
| NCT07412262 |
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small… |
Non-Small Cell Lung Cancer |
Not Yet Recruiting |
| NCT04015778 |
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and… |
Non Small Cell Lung Cancer |
Active, Not Recruiting |
| NCT05957510 |
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From… |
Small-cell Lung Cancer |
Active, Not Recruiting |
| NCT07750704 |
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line… |
ALK Positive Non-small Cell Lung Cancer |
Not Yet Recruiting |
| Not specified |
| NCT04286841 |
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China |
Immunotherapy |
Recruiting |
| NCT07652125 |
RGL-270 + ICI in Advanced NSCLC |
NSCLC |
Recruiting |
| NCT07696832 |
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for… |
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC |
Recruiting |
| NCT06709274 |
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC |
Non-Small Cell Lung Cancer |
Not Yet Recruiting |
| NCT07198620 |
A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China |
Lung Cancer (NSCLC) |
Not Yet Recruiting |